The stock has a 36-month beta value of 0.22. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRNA is 76.70M, and at present, short sellers hold a 9.30% of that float. On June 11, 2025, the average trading volume of VRNA was 1.40M shares.
VRNA) stock’s latest price update
Verona Pharma Plc ADR (NASDAQ: VRNA)’s stock price has soared by 5.35 in relation to previous closing price of 86.78. Nevertheless, the company has seen a gain of 8.86% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-10 that Ohtuvayre’s rapid US launch has driven explosive revenue growth, with Q1 2025 sales up 95% sequentially and refill rates signaling strong patient demand. With blockbuster potential, Wall Street projects Verona Pharma’s sales to reach $1 billion by 2028, fueled by its safety profile and the unmet needs of those 398 million COPD sufferers worldwide. Global expansion, robust patent protection, and a growing pipeline position Verona for sustained high-margin growth and possible buyout interest.
VRNA’s Market Performance
Verona Pharma Plc ADR (VRNA) has seen a 8.86% rise in stock performance for the week, with a 35.38% gain in the past month and a 35.24% surge in the past quarter. The volatility ratio for the week is 1.74%, and the volatility levels for the past 30 days are at 2.15% for VRNA. The simple moving average for the past 20 days is 16.38% for VRNA’s stock, with a 79.41% simple moving average for the past 200 days.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with TD Cowen repeating the rating for VRNA by listing it as a “Buy.” The predicted price for VRNA in the upcoming period, according to TD Cowen is $100 based on the research report published on April 28, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $80. The rating they have provided for VRNA stocks is “Overweight” according to the report published on April 21st, 2025.
ROTH MKM gave a rating of “Buy” to VRNA, setting the target price at $68 in the report published on January 10th of the current year.
VRNA Trading at 31.95% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 4.21% of gains for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from Hahn Mark W, who sale 204,864 shares at the price of $9.33 back on May 29 ’25. After this action, Hahn Mark W now owns 12,678,992 shares of Verona Pharma Plc ADR, valued at $1,911,668 using the latest closing price.
Hahn Mark W, the Chief Financial Officer of Verona Pharma Plc ADR, sale 162,704 shares at $9.30 during a trade that took place back on May 28 ’25, which means that Hahn Mark W is holding 12,883,856 shares at $1,513,294 based on the most recent closing price.
Stock Fundamentals for VRNA
Current profitability levels for the company are sitting at:
- -1.16 for the present operating margin
- 0.95 for the gross margin
The net margin for Verona Pharma Plc ADR stands at -1.38. The total capital return value is set at -0.29. Equity return is now at value -72.73, with -40.26 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -56.16. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -11.7.
Currently, EBITDA for the company is -142.19 million with net debt to EBITDA at 2.27. When we switch over and look at the enterprise to sales, we see a ratio of 62.35. The receivables turnover for the company is 1.91for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.86.
Conclusion
To sum up, Verona Pharma Plc ADR (VRNA) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
